{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:45:16Z","timestamp":1776231916165,"version":"3.50.1"},"reference-count":184,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple myeloma (MM) is a clonal hematologic malignancy characterized by plasma cell proliferation in the bone marrow. One of the most common clinical presentations is skeletal-related events (SREs), characterized by osteolysis of the bone, leading to a significant morbidity and mortality. The main aim of this review article is to provide an overview of the pathogenesis and evidence-based, guideline-recommended treatment of SREs. MM bone homeostasis is altered by numerous pathways and cytokines, leading to the pathogenesis of bone and osteolytic lesions. Historically, bisphosphonates were the mainstay of treatment, but due to toxicities and contraindications in renal impairment, denosumab\u2014a monoclonal antibody targeting the RANKL-RANK axis, given once per month\u2014may have become the treatment of choice, especially with three biosimilars being approved, yet adverse events may be troublesome. Furthermore, it seems that anti-MM-directed therapy has an impact on bone turnover, yet the results are premature. However, despite basic research unraveling novel targets such as micro ribonucleic acids, translational research and randomized clinical trials are lagging behind, making this area an unmet need\u2014despite the fact that precision, risk-adapted, biomarker- and imaging-driven medicine should be a valid clinical goal in this setting.<\/jats:p>","DOI":"10.3389\/fonc.2026.1722230","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:46:38Z","timestamp":1776228398000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone-modifying therapy in multiple myeloma: a comprehensive review"],"prefix":"10.3389","volume":"16","author":[{"given":"Martina","family":"Bogelji\u0107 Patekar","sequence":"first","affiliation":[{"name":"Division of Hematology, Clinical Hospital Merkur","place":["Zagreb, Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibor","family":"Milunovi\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology, Clinical Hospital Merkur","place":["Zagreb, Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Mandac Smoljanovi\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology, Clinical Hospital Merkur","place":["Zagreb, Croatia"]},{"name":"School of Medicine in Zagreb, University of Zagreb","place":["Zagreb, Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Ba\u0161i\u0107 Kinda","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, University Hospital Zagreb","place":["Zagreb, Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slobodanka","family":"Ostoji\u0107 Koloni\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology, Clinical Hospital Merkur","place":["Zagreb, Croatia"]},{"name":"School of Medicine in Zagreb, University of Zagreb","place":["Zagreb, Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delfa","family":"Radi\u0107-Kri\u0161to","sequence":"additional","affiliation":[{"name":"Division of Hematology, Clinical Hospital Merkur","place":["Zagreb, Croatia"]},{"name":"School of Medicine in Zagreb, University of Zagreb","place":["Zagreb, Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slavko","family":"Ga\u0161parov","sequence":"additional","affiliation":[{"name":"School of Medicine in Zagreb, University of Zagreb","place":["Zagreb, Croatia"]},{"name":"Clinical Department of Pathology and Cytology, Clinical Hospital Merkur","place":["Zagreb, Croatia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhamed","family":"Baljevic","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center","place":["Nashville, TN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100441","article-title":"Fifth edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: B-cell neoplasms","volume":"37","author":"Medeiros","year":"2024","journal-title":"Mod Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"B3","unstructured":"Cancer stat facts: myeloma\n          \n          \n          \n          2025"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cells11152308","article-title":"Bone disease in multiple myeloma: biologic and clinical implications","volume":"11","author":"Bernstein","year":"2022","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.01.027","article-title":"The pathogenesis of the bone disease of multiple myeloma","volume":"42","author":"Edwards","year":"2008","journal-title":"Bone"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: Results of the IMAJEM study","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.657","article-title":"Regulation of bone homeostasis: signaling pathways and therapeutic targets","volume":"5","author":"Wu","year":"2024","journal-title":"MedComm (2020)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1615\/critreveukargeneexpr.v19.i3.40","article-title":"Bone modeling and remodeling","volume":"19","author":"Seeman","year":"2009","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41421-024-00689-6","article-title":"Cell signaling and transcriptional regulation of osteoblast lineage commitment, differentiation, bone formation, and homeostasis","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Discov"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.abb.2014.05.003","article-title":"Osteoblast and osteocyte: games without frontiers","volume":"561","author":"Capulli","year":"2014","journal-title":"Arch Biochem Biophys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1122","article-title":"Genetic regulation of osteoclast development and function","volume":"4","author":"Teitelbaum","year":"2003","journal-title":"Nat Rev Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","article-title":"RANKL-RANK signaling in osteoclastogenesis and bone disease","volume":"12","author":"Wada","year":"2006","journal-title":"Trends Mol Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-022-08190-7","article-title":"Bone cells and their role in physiological remodeling","volume":"50","author":"Maciel","year":"2023","journal-title":"Mol Biol Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad711","article-title":"New horizons: translational aspects of osteomorphs","volume":"109","author":"Park-Min","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010132","article-title":"Regulation of TNF-induced osteoclast differentiation","volume":"11","author":"Yao","year":"2021","journal-title":"Cells"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1702413","article-title":"Novel aspects of biochemical assessment of bone remodeling and mineralization","volume":"16","author":"Leszczy\u0144ska","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.259","article-title":"Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20","volume":"30","author":"Palma","year":"2016","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/jcb.10613","article-title":"Activin A stimulates IkappaB-alpha\/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors","volume":"90","author":"Sugatani","year":"2003","journal-title":"J Cell Biochem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11176","article-title":"TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand","volume":"106","author":"Lam","year":"2000","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdsr.2021.08.006","article-title":"Pathogenesis and treatment of multiple myeloma bone disease","volume":"57","author":"Hiasa","year":"2021","journal-title":"Jpn Dent Sci Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2067","article-title":"Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1","volume":"72","author":"Fowler","year":"2012","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds068","article-title":"Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy","volume":"23","author":"Terpos","year":"2012","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.26512","article-title":"Current approaches to management of newly diagnosed multiple myeloma","volume":"97","author":"Goel","year":"2022","journal-title":"Am J Hematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.semradonc.2024.10.004","article-title":"Radiation for multiple myeloma in the era of novel agents: indications, safety, and dose selection","volume":"35","author":"Zhang","year":"2025","journal-title":"Semin Radiat Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.21037\/jss-24-54","article-title":"Surgical management of spinal multiple myeloma: insights from the National Inpatient Sample database","volume":"10","author":"Zehri","year":"2024","journal-title":"J Spine Surg"},{"key":"B41","doi-asserted-by":"publisher","first-page":"100999","DOI":"10.1016\/j.blre.2022.10099","article-title":"The use of bone-modifying agents in multiple myeloma","volume":"57","author":"Hussain","year":"2023","journal-title":"Blood Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17256","article-title":"Controversies in the use of new bone-modifying therapies in multiple myeloma","volume":"193","author":"Terpos","year":"2021","journal-title":"Br J Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115715","article-title":"Clodronate","volume":"143","author":"McCloskey","year":"2021","journal-title":"Bone"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.8.1397","article-title":"Effect of daily etidronate on the osteolysis of multiple myeloma","volume":"9","author":"Belch","year":"1991","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93075-x","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00223-014-9903-2","article-title":"Effect of clodronate treatment on risk of fracture: a systematic review and meta-analysis","volume":"95","author":"Frediani","year":"2014","journal-title":"Calcif Tissue Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Terpos","year":"2011","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003188","article-title":"Bisphosphonates in multiple myeloma","volume":"4","author":"Djulbegovic","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.924117","article-title":"Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma","volume":"56","author":"Sanfilippo","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003188.pub3","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06350-w","article-title":"Comparing medication adherence in patients receiving bisphosphonates for preventing fragility fractures: a comprehensive systematic review and network meta-analysis","volume":"33","author":"Bastounis","year":"2022","journal-title":"Osteoporos Int"},{"key":"B58","unstructured":"Osteocyte Apoptosis Attracts Myeloma Cells to Bone and Supports Progression through Regulation of the Bone Marrow Microenvironment\n          \n          \n            \n              Trotter\n              TN\n            \n            \n              Fok\n              M\n            \n            \n              Gibson\n              JT\n            \n            \n              Peker\n              D\n            \n            \n              Javed\n              A\n            \n            \n              Yang\n              Y\n            \n          \n          \n          2016"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0236","article-title":"Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis","volume":"104","author":"Mori","year":"2004","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4361","article-title":"Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma","volume":"67","author":"Vanderkerken","year":"2007","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-0974-x","article-title":"Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications","volume":"60","author":"Terpos","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003188.pub4","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00236","article-title":"Use of bone-modifying agents in myeloma and bone metastases: how recent dosing interval studies have affected our practice","volume":"14","author":"Campagnaro","year":"2018","journal-title":"J Oncol Pract"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"B68","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: A randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1934-0","article-title":"Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors","volume":"21","author":"Van den Wyngaert","year":"2013","journal-title":"Support Care Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.02.007","article-title":"Prolonged use of zoledronic acid (4 years) did not improve outcome in multiple myeloma patients","volume":"17","author":"Avil\u00e8s","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B71","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41408-024-01046-2","article-title":"In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease","volume":"14","author":"Lund","year":"2024","journal-title":"Blood Cancer J"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1864","article-title":"Bone marker-directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: results of the Z-MARK study","volume":"22","author":"Raje","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1186\/s12885-024-13284-5","article-title":"Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.05.010","article-title":"Renal impairment at diagnosis in myeloma: patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand myeloma and related diseases registry","volume":"19","author":"Ho","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B76","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12903-024-03943-1","article-title":"Oral health, dental treatment, and medication related osteonecrosis of the jaw in multiple myeloma - a longitudinal cohort study","volume":"24","author":"Olofsson","year":"2024","journal-title":"BMC Oral Health"},{"key":"B77","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12910-025-01361-8","article-title":"Low awareness of medication-related osteonecrosis of the jaw among dentists: a systematic review with a medical and bioethical perspective","volume":"27","author":"Coppini","year":"2026","journal-title":"BMC Med Ethics"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2025.105871","article-title":"How publication bias overestimates the risk of atypical femoral fracture and osteonecrosis of the jaw associated with bisphosphonate use: A meta-epidemiological study","volume":"92","author":"Gougeon","year":"2025","journal-title":"Joint Bone Spine"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016649368","article-title":"Identification of risk factors for bisphosphonate-associated atypical femoral fractures and osteonecrosis of the jaw in a pharmacovigilance database","volume":"50","author":"Bejhed","year":"2016","journal-title":"Ann Pharmacother"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2007.01580.x","article-title":"Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid","volume":"38","author":"Chennuru","year":"2008","journal-title":"Intern Med J"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0267","article-title":"Is severe hypocalcemia immediately life threatening","volume":"7","author":"Duval","year":"2018","journal-title":"Endocr Connect"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl181","article-title":"Management of the side-effects of intravenous bisphosphonates: targeting the serum parathyroid hormone elevation","volume":"17","author":"Berruti","year":"2006","journal-title":"Ann Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.137703","article-title":"Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients","volume":"326","author":"Marathe","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds175","article-title":"Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid","volume":"23","author":"Vadhan-Raj","year":"2012","journal-title":"Ann Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.96","article-title":"Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial","volume":"6","author":"Raje","year":"2016","journal-title":"Blood Cancer J"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjaf037","article-title":"Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures","volume":"40","author":"Kumar","year":"2025","journal-title":"J Bone Miner Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07601-2","article-title":"Trends in serum phosphate, calcium, and parathyroid hormone levels according to renal function following denosumab","volume":"36","author":"Lee","year":"2025","journal-title":"Osteoporos Int"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.28239","article-title":"Hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"},{"key":"B99","doi-asserted-by":"publisher","first-page":"29","DOI":"10.7326\/M24-0013","article-title":"The effect of denosumab on risk for emergently treated hypocalcemia by stage of chronic kidney disease: a target trial emulation","volume":"178","author":"Bird","year":"2025","journal-title":"Ann Intern Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1586626","article-title":"Risk factors for denosumab-related osteonecrosis of the jaw: a pharmacovigilance study using the U.S. FDA adverse event reporting system database","volume":"16","author":"Bai","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz295","article-title":"Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society","volume":"105","author":"van de Laarschot","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.11.037","article-title":"The role of anatomic and functional staging in myeloma: description of Durie\/Salmon plus staging system","volume":"42","author":"Durie","year":"2006","journal-title":"Eur J Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.62347\/NLLV9295","article-title":"Recent advances in imaging and artificial intelligence (AI) for quantitative assessment of multiple myeloma","volume":"14","author":"Liu","year":"2024","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.08.012","article-title":"Favorable long-term outcomes with autologous stem cell transplantation for high-risk multiple myeloma patients with a positive result on 18F-FDG PET\/CT at baseline","volume":"22","author":"Cho","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40644-023-00625-z","article-title":"Semi-quantitative FDG parameters predict survival in multiple myeloma patients without autologous stem cell transplantation","volume":"23","author":"Lee","year":"2023","journal-title":"Cancer Imaging"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-019-06469-1","article-title":"MRI versus 18F-FDG-PET\/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance","volume":"30","author":"Lecouvet","year":"2020","journal-title":"Eur Radiol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6911246","article-title":"Radiomics models based on magnetic resonance imaging for prediction of the response to bortezomib-based therapy in patients with multiple myeloma","volume":"2022","author":"Li","year":"2022","journal-title":"BioMed Res Int"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.28962","article-title":"Quantitative analysis of whole-body MRI for accessing the degree of diffuse infiltration patterns and identifying high risk cases of newly diagnosed multiple myeloma","volume":"59","author":"Sun","year":"2024","journal-title":"J Magn Reson Imaging"},{"key":"B112","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.07.028","article-title":"Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6","volume":"33","author":"Hongming","year":"2009","journal-title":"Leuk Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20170181","article-title":"Diagnostic usefulness of low-dose lumbar multi-detector CT with iterative reconstruction in trauma patients: a comparison with standard-dose CT","volume":"90","author":"Lee","year":"2017","journal-title":"Br J Radiol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12880-016-0143-y","article-title":"Radiation dosimetry of 18F-FDG PET\/CT: incorporating exam-specific parameters in dose estimates","volume":"16","author":"Quinn","year":"2016","journal-title":"BMC Med Imaging"},{"key":"B116","unstructured":"Cancer facts and figures 2025"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary Malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28481","article-title":"The effects of bortezomib on bone disease in patients with multiple myeloma","volume":"120","author":"Mohty","year":"2014","journal-title":"Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br J Haematol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01599.x","article-title":"Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma","volume":"86","author":"Delforge","year":"2011","journal-title":"Eur J Haematol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2007.12.006","article-title":"Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma","volume":"42","author":"Qiang","year":"2008","journal-title":"Bone"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.267","article-title":"VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT","volume":"28","author":"Terpos","year":"2014","journal-title":"Leukemia"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.05.022","article-title":"Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro","volume":"38","author":"Li","year":"2014","journal-title":"Leuk Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061257","article-title":"Carfilzomib improves bone metabolism in patients with advanced relapsed\/refractory multiple myeloma: results of the CarMMa study","volume":"13","author":"Terpos","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020323","article-title":"Ixazomib improves bone remodeling and counteracts sonic Hedgehog signaling inhibition mediated by myeloma cells","volume":"12","author":"Tibullo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4807","article-title":"Increased bone volume by ixazomib in multiple myeloma: 3-month results from an open label phase 2 study","volume":"38","author":"Diaz-delCastillo","year":"2023","journal-title":"J Bone Miner Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.exphem.2012.11.005","article-title":"Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL\/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules","volume":"41","author":"Bolzoni","year":"2013","journal-title":"Exp Hematol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19265","article-title":"Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"B131","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/ajh.23577","article-title":"The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed\/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group","volume":"89","author":"Terpos","year":"2014","journal-title":"Am J Hematol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112768","article-title":"Daratumumab improves bone turnover in relapsed\/refractory multiple myeloma; phase 2 study \"REBUILD","volume":"14","author":"Terpos","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple myeloma, version 2.2016: clinical practice guidelines in oncology","volume":"13","author":"Anderson","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update","volume":"36","author":"Anderson","year":"2018","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"B137","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) for multiple myeloma v1.2026","author":"Kumar","year":"2025","journal-title":"National Comprehensive Cancer Network"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"key":"B139","unstructured":"Narlumosbart compared with denosumab in patients with multiple myeloma bone disease identifier NCT06314698"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01985-3","article-title":"Narlumosbart: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05639-y","article-title":"Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study","volume":"32","author":"Tominaga","year":"2021","journal-title":"Osteoporos Int"},{"key":"B142","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40520-024-02921-5","article-title":"Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023","volume":"37","author":"Liu","year":"2025","journal-title":"Aging Clin Exp Res"},{"key":"B143","unstructured":"A study of romosozumab in women with multiple myeloma and osteoporosis indetifier NCT05775094"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13056","article-title":"A phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br J Haematol"},{"key":"B146","unstructured":"A double-blind, placebo-controlled, randomized phase 2 study of BHQ880, an anti-Dickkopf1 (DKK1) monoclonal antibody (mAb), in patients with untreated multiple myeloma and renal insufficiency indentifier NCT01337752"},{"key":"B147","unstructured":"A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with intravenous BHQ880, a fully human, anti-Dickkopf1 (DKK1) neutralizing antibody in previously untreated patients with high-risk, smoldering multiple myeloma indetifier NCT01337752"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br J Haematol"},{"key":"B149","unstructured":"Sotatercept (ACE-011) with lenalidomide or pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma identifier NCT01562405"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25919","article-title":"Teriparatide (recombinant human parathyroid hormone 1-34) therapy in myeloma patients with severe osteoporosis and fractures despite effective anti-myeloma therapy and bisphosphonates: a pilot study","volume":"95","author":"Diamond","year":"2020","journal-title":"Am J Hematol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013657","article-title":"Parathyroid hormone mediates hematopoietic cell expansion through interleukin-6","volume":"5","author":"Pirih","year":"2010","journal-title":"PloS One"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103784","article-title":"Epigenetics in autoimmune diseases: Unraveling the hidden regulators of immune dysregulation","volume":"30","author":"Bagni","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70337","article-title":"Diagnostic and prognostic accuracy of MiRNAs in pancreatic cancer: a systematic review and meta-analysis","volume":"29","author":"Hasani","year":"2025","journal-title":"J Cell Mol Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2024-0322","article-title":"MiRNAs as potential biomarkers in early breast cancer detection: a systematic review","volume":"17","author":"Mihai","year":"2024","journal-title":"J Med Life"},{"key":"B155","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1186\/s12885-024-12528-8","article-title":"Comparison of the diagnostic value of various microRNAs in blood for colorectal cancer: a systematic review and network meta-analysis","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Cancer"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27486","article-title":"An overview of microRNAs: Biology, functions, therapeutics, and analysis methods","volume":"234","author":"Saliminejad","year":"2019","journal-title":"J Cell Physiol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br J Cancer"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154715","article-title":"Decoding the role of miRNAs in multiple myeloma pathogenesis: a focus on signaling pathways","volume":"248","author":"Yehia","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B159","doi-asserted-by":"publisher","first-page":"10957","DOI":"10.1038\/s41598-021-90424-y","article-title":"Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data","volume":"11","author":"Katiyar","year":"2021","journal-title":"Sci Rep"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24306","article-title":"miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease","volume":"228","author":"Rossi","year":"2013","journal-title":"J Cell Physiol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-558007","article-title":"Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model","volume":"124","author":"Reagan","year":"2014","journal-title":"Blood"},{"key":"B162","article-title":"MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2","volume":"8","author":"Wu","year":"2016","journal-title":"Am J Transl Res"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215258","article-title":"Circulating microRNAs correlate with multiple myeloma and skeletal osteolytic lesions","volume":"13","author":"Moura","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222313144","article-title":"A cancer-related microRNA signature shows biomarker utility in multiple myeloma","volume":"22","author":"Papanota","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052375","article-title":"Multiple myeloma bone disease: implication of microRNAs in its molecular background","volume":"22","author":"Papanota","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020449","article-title":"Extracellular vesicle microRNAs contribute to the osteogenic inhibition of mesenchymal stem cells in multiple myeloma","volume":"12","author":"Raimondo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826030-00007","article-title":"Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases","volume":"26","author":"McKeage","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"B168","unstructured":"Pamidronate sodium"},{"key":"B169","unstructured":"Xgeva prices, coupons, copay cards & patient assistance"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1445634","article-title":"A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America","volume":"21","author":"Raje","year":"2018","journal-title":"J Med Econ"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1606002","article-title":"A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy","volume":"22","author":"Terpos","year":"2019","journal-title":"J Med Econ"},{"key":"B172","unstructured":"Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)"},{"key":"B173","unstructured":"Denosumab"},{"key":"B174","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/14712598.2024.2308645","article-title":"Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males","volume":"24","author":"Vogg","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"B175","unstructured":"Denosumab. Wyost label"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2316846","article-title":"A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT-P41 and reference denosumab in healthy males","volume":"24","author":"Kim","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"B177","unstructured":"Celltrion receives U.S. FDA approval for STOBOCLO\u00ae (denosumab-bmwo) and OSENVELT\u00ae (denosumab-bmwo) biosimilars referencing PROLIA\u00ae and XGEVA\u00ae"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2273510","article-title":"A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects","volume":"32","author":"Lee","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B179","unstructured":"FDA, EMA approve second pair of denosumab biosimilars"},{"key":"B180","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1208\/s12249-025-03038-2","article-title":"Biosimilars: a critical review of development, regulatory landscape, and clinical implications","volume":"26","author":"Monga","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjae016","article-title":"Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study","volume":"39","author":"Jeka","year":"2024","journal-title":"J Bone Miner Res"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07161-x","article-title":"Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, phase 3 trial in postmenopausal women with osteoporosis","volume":"35","author":"Reginster","year":"2024","journal-title":"Osteoporos Int"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117371","article-title":"SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial","volume":"192","author":"Chung","year":"2025","journal-title":"Bone"},{"key":"B184","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s11033-024-09892-w","article-title":"Navigating the clinical landscape: update on the diagnostic and prognostic biomarkers in multiple myeloma","volume":"51","author":"Raghunathachar","year":"2024","journal-title":"Mol Biol Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1722230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:46:53Z","timestamp":1776228413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1722230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":184,"alternative-id":["10.3389\/fonc.2026.1722230"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1722230","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1722230"}}